Skip to main content
SpringerLink
Log in

Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies

  • Protocol
  • First Online:
Book cover Leukemia Stem Cells

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2185))

Abstract

Next-generation sequencing (NGS) of immunoglobulin (IG) and T cell receptor (TR) rearrangements represents a modern alternative to classical RQ-PCR-based minimal residual disease (MRD) detection. The same primer sets and conditions can be used for all patients, which is undoubtedly one of the most important benefits of NGS, not only reducing the labor required to perform the analysis but also enabling the assay to comply with the upcoming EU IVD regulation. So far, only one standardized academic protocol for this task has been published, developed, and validated within the EuroClonality-NGS working group. In this chapter we describe the materials and methods for amplicon library preparation for sequencing on Illumina MiSeq, and the bioinformatic pipeline for this protocol.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. van der Velden VHJ, van Dongen JJM (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. In: Methods in molecular biology, Clifton, NJ, pp 115–150

    Google Scholar 

  2. van der Velden VHJ, Cazzaniga G, Schrauder A et al (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604–611. https://doi.org/10.1038/sj.leu.2404586

    Article  CAS  PubMed  Google Scholar 

  3. Gomez-Arteaga A, Guzman ML (2018) Minimal residual disease in acute myeloid leukemia. In: Advances in experimental medicine and biology. National Center for Biotechnology Information, Bethesda, MD, pp 111–125

    Google Scholar 

  4. Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131:1275–1291. https://doi.org/10.1182/blood-2017-09-801498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Voso MT, Ottone T, Lavorgna S et al (2019) MRD in AML: the role of new techniques. Front Oncol 9:655. https://doi.org/10.3389/fonc.2019.00655

    Article  PubMed  PubMed Central  Google Scholar 

  6. Steensma DP (2018) Clinical consequences of clonal hematopoiesis of indeterminate potential. Hematology 2018:264–269. https://doi.org/10.1182/asheducation-2018.1.264

    Article  PubMed  PubMed Central  Google Scholar 

  7. Karner K, George TI, Patel JL (2019) Current aspects of clonal hematopoiesis: implications for clinical diagnosis. Ann Lab Med 39:509. https://doi.org/10.3343/alm.2019.39.6.509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Brüggemann M, Kotrová M, Knecht H et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 33(9):2241–2253. https://doi.org/10.1038/s41375-019-0496-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kotrova M, Muzikova K, Mejstrikova E et al (2015) The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood 126:1045. https://doi.org/10.1182/BLOOD-2015-07-655159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Faham M, Zheng J, Moorhead M et al (2012) Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120:5173–5180. https://doi.org/10.1182/blood-2012-07-444042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wu D, Sherwood A, Fromm JR et al (2012) High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 4:134ra63–134ra63. https://doi.org/10.1126/scitranslmed.3003656

    Article  CAS  PubMed  Google Scholar 

  12. Wu D, Emerson RO, Sherwood A et al (2014) Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 20:4540–4548. https://doi.org/10.1158/1078-0432.CCR-13-3231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Carlson CS, Emerson RO, Sherwood AM et al (2013) Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 4:2680. https://doi.org/10.1038/ncomms3680

    Article  CAS  PubMed  Google Scholar 

  14. Knecht H, Reigl T, Kotrová M et al (2019) Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33(9):2254–2265. https://doi.org/10.1038/s41375-019-0499-4

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bystry V, Reigl T, Krejci A, et al (2016) ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics 33:btw634. doi:https://doi.org/10.1093/bioinformaticsBioinformatics/btw634

Download references

Author information

Authors and Affiliations

  1. Unit for Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, Kiel, Germany

    Michaela Kotrova, Nikos Darzentas, Christiane Pott & Monika Brüggemann

Authors
  1. Michaela Kotrova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikos Darzentas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christiane Pott
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monika Brüggemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On Behalf of the EuroClonality-NGS Working Group

Corresponding author

Correspondence to Monika Brüggemann .

Editor information

Editors and Affiliations

  1. Immune System Development and Function Unit, Centro de Biologia Molecular "Severo Ochoa", (CSIC/UAM), Madrid, Spain

    César Cobaleda

  2. IBMCC, Laboratory 13, CSIC/Universidad de Salamanca, Salamanca, Spain

    Isidro Sánchez-García

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Kotrova, M., Darzentas, N., Pott, C., Brüggemann, M., On Behalf of the EuroClonality-NGS Working Group. (2021). Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies. In: Cobaleda, C., Sánchez-García, I. (eds) Leukemia Stem Cells. Methods in Molecular Biology, vol 2185. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0810-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0810-4_7

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0809-8

  • Online ISBN: 978-1-0716-0810-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation